Evidence map›Paper›PMID 42427603›Full record

ArticlebioRxiv : the preprint server for biology2026

Variable latency between the founder genetic event and rhabdoid tumor expansion.

Mònica Sánchez-Guixé, Alex Cebria-Xart, Naomi Fabre, Carlos J Rodriguez-Hernandez, Morena Pinheiro-Santin, Cinzia Lavarino, Jarno Drost, Ruben Van Boxtel, Núria López-Bigas, Alexandra Avgustinova and 1 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mònica Sánchez-GuixéInstitut de Recerca Sant Joan de Déu, Barcelona 08950, Spain.ORCID 0000-0002-9430-4413
Alex Cebria-XartInstitut de Recerca Sant Joan de Déu, Barcelona 08950, Spain.
Naomi FabreInstitut de Recerca Sant Joan de Déu, Barcelona 08950, Spain.
Carlos J Rodriguez-HernandezInstitut de Recerca Sant Joan de Déu, Barcelona 08950, Spain.
Morena Pinheiro-SantinInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain.
Cinzia LavarinoInstitut de Recerca Sant Joan de Déu, Barcelona 08950, Spain.
Jarno DrostPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Ruben Van BoxtelPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Núria López-BigasInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain.
Alexandra AvgustinovaInstitut de Recerca Sant Joan de Déu, Barcelona 08950, Spain.
Abel González-PérezInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain.

Funding

PROMINENT - IRBOT2CA278668 · NCI · FUNDACIO INSTITUT DE RECERCA BIOMEDICA · PI LOPEZ-BIGAS, NURIA · 2022 to 2024
$1.0M
NCI NIH HHS OT2 CA278668
6 · The paper itself

Abstract

Rhabdoid tumors are very aggressive rare pediatric cancers with poor survival affecting very young children. They are characterized by the bi-allelic loss of

Identifiers

PMID42427603
PMCPMC13345113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.